Journal Of Clinical Oncology (jco) Podcast

A Clear Answer to the Wrong Question

Informações:

Synopsis

The AVAPERL trial reveals a significant improvement in progression-free survival with the combination of pemetrexed/bevacizumab compared with bevacizumab alone as maintenance therapy for advanced non- small-cell lung cancer, but the clinically relevant endpoint remains overall survival.